| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_280d87031f0c5786de1808713a1b76b7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-72 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-72 |
| filingDate |
2002-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2005-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21a085b172cdc70c6aeba347a5ddc299
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c009b23f01c4e005b0456d55b579ba5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e37517e4ab977c741d63b101e645bdd4 |
| publicationDate |
2005-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-6911531-B2 |
| titleOfInvention |
Antibodies directed towards a novel human EP prostaglandin receptor |
| abstract |
A gene encoding the HP4 human prostaglandin receptor is disclosed. The protein encoded by this gene exhibits significant sequence identity with other prostaglandin receptors. The HP4 receptor, when expressed in eukaryotic cells, is capable of binding prostaglandins and their analogs and stimulating adenylate cyclase activity in response to prostaglandins. Also disclosed are antisense agents able to decrease or prevent translation of a human HP4 prostaglandin receptor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10435465-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2003203435-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11649281-B2 |
| priorityDate |
1994-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |